Phase 3 N=339 Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure
Pneumothorax
Primary: Incidence Rate of Treatment Success — 126; 94 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=50 The Effect of Adding Sufentanyl to Bupivacaine in Transversus Abdominis Plane Block to Reduce the Narcotic Dosage and Pain After Cesarean Delivery
Pain
Primary: Narcotic Dosage
Phase 3 N=379 Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents
Bipolar Disorder
Primary: Clinical Global Impressions-Bipolar Mania Improvement — 2.49; 2.73; 1.70 units on a scale
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
Phase 4 N=69 A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
Asthma
Primary: Area Under the Curve (AUC) of Percent Change in Forced Expiratory Volume in 1 Second (FEV1) Over a 1-hour Cat Allergen Exposure From Pre-challenge at Week 16 — 15.03…
N/A N=20 The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
Ovarian Hyperstimulation Syndrome
Primary: Volume of Ascites in the Abdomen is Indicative of the Severity of OHSS — 10 cc (volume of ascites)
Phase 2 N=26 Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Melanoma (Skin)
Primary: Clinical Tumor Regression — 1; 1; 9; 2 Participants
Phase 3 N=655 Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus
Primary: Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) — -0.96; -1.15; -1.71; -1.56 percentage of glycosylated hemoglobin — p=<0.001
Phase 4 N=146 The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
Schizophrenia
Primary: Mean Difference in Body Weight Change Between Participants Assigned to Metformin and Participants Assigned to Placebo — -1.0; -3.0 kilograms
Phase 2 N=10 Flumazenil for the Treatment of Primary Hypersomnia
Hypersomnia · Primary Hypersomnia · Idiopathic Hypersomnia
Primary: Change in Psychomotor Vigilance Task (PVT) Median Reaction Time — -9.86; -4.46 msec — p=0.77
Phase 1 N=9 Single DermaVir Immunization in HIV-1 Infected Patients on HAART
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
Phase 4 N=9 Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A
Hemophilia A
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. One-Stage Activated Partial Thromboplastin Time (aPTT) -Based Assay Performed at Central…
Phase 3 N=278 Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks — -0.27; -0.84 Percentage — p=< 0.0001
Phase 3 N=784 Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — 0.15; -0.52; -0.56; -0.65 percentage glycosylated hemoglobin — p=<0.001
Phase 3 N=463 Tiotropium Bromide in Cystic Fibrosis
Cystic Fibrosis
Primary: Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0-4 Hours (AUC0-4h) Response — 0.87; 2.51 Percent of predicted — p=0.092